Background: Migraine is a highly prevalent neurological disorder. Conventional therapies may be limited by side effects and suboptimal efficacy. Cannabidiol (CBD) has emerged as a potential alternative therapy with a more favorable safety profile. Methods: In this 12-week prospective observational cohort study, we evaluated the safety, feasibility, and preliminary efficacy of two full-spectrum CBD-rich oils—industrial and artisanal—for chronic migraine in 40 individuals that began self-medicating with either oil (N = 20 per group), provided through an existing initiative by an industrial company and a patient association. The oil was titrated individually to reach a target dose of 100 mg/day of CBD. Assessments were conducted using the Migraine Disability Assessment Questionnaire (MIDAS), Headache Impact Test (HIT-6), Mini Sleep Questionnaire (MSQ), and the World Health Organization Quality of Life—5-item version (WHOQOL-5). Results: Both formulations led to improvements in migraine-related disability, headache impact, quality of life, quality of sleep, and subjective well-being. Adverse events occurred at similar rates across groups. Conclusions: In sum, full-spectrum CBD-rich oil—both industrial and artisanal—appears effective in reducing migraine burden in individuals with chronic migraine, while maintaining an acceptable side effects profile. These findings support the need for randomized controlled trials to determine the lowest and most effective regimens, and cannabinoid compositions.
- Open Access
- Article
Improved Migraine Disability, Sleep Quality, and Well-Being in Individuals with Chronic Migraine Self-Administering Artisanal or Industrial Full-Spectrum Cannabidiol-Rich Oils: An Observational Cohort Study
- Linério Ribeiro de Novais Júnior 1,*,
- Larissa Mendes da Silva 1,
- Vicente Meneguzzo 1,
- Suelen de Souza Ramos 1,
- Lara Rodrigues da Rosa 1,
- Tiago Odilio de Souza 1,
- João Victor Simão 1,
- Alisson Reuel da Silva 1,
- Josiel Mack 1,
- Kelser de Souza Kock 1,
- Mariana Pereira de Souza Goldim 1,
- Antonio Inserra 1,2,
- Rafael Mariano de Bitencourt 1
Author Information
Received: 04 Nov 2025 | Revised: 24 Dec 2025 | Accepted: 24 Dec 2025 | Published: 15 Jan 2026
Abstract
Keywords
cannabidiol | cannabinoids | chronic migraine | migraine disorders | full-spectrum | cannabis oil | observational study | prospective cohort | artisanal | industrial
References
- 1.
Dong, L.; Dong, W.; Jin, Y.; et al. The Global Burden of Migraine: A 30-Year Trend Review and Future Projections by Age, Sex, Country, and Region. Pain. Ther. 2025, 14, 297–315. https://doi.org/10.1007/s40122-024-00690-7.
- 2.
Steiner, T.J.; Stovner, L.J. Global epidemiology of migraine and its implications for public health and health policy. Nat. Rev. Neurol. 2023, 19, 109–117. https://doi.org/10.1038/s41582-022-00763.
- 3.
Arnold, M. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018, 38, 1–211. https://doi.org/10.1177/0333102417738202.
- 4.
Puledda, F.; Silva, E.M.; Suwanlaong, K.; et al. Migraine: From pathophysiology to treatment. J. Neurol. 2023, 270, 3654–3666. https://doi.org/10.1007/s00415-023-11706-1.
- 5.
Silvestro, M.; Iannone, L.F.; Orologio, I.; et al. Migraine treatment: Towards new pharmacological targets. Int. J. Mol. Sci. 2023, 24, 12268. https://doi.org/10.3390/ijms241512268.
- 6.
Greco, R.; Demartini, C.; Zanaboni, A.M.; et al. The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain. Headache J. Head Face Pain 2022, 62, 227–240. https://doi.org/10.1111/head.14267.
- 7.
Greco, R.; Demartini, C.; Zanaboni, A.M.; et al. Peripheral changes of endocannabinoid system components in episodic and chronic migraine patients: A pilot study. Cephalalgia 2021, 41, 185–196. https://doi.org/10.1177/0333102420949201.
- 8.
Russo, E.B. Clinical endocannabinoid deficiency reconsidered: Current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res. 2016, 1, 154–165. https://doi.org/10.1089/can.2016.0009.
- 9.
Cristino, L.; Bisogno, T.; Di Marzo, V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat. Rev. Neurol. 2020, 16, 9–29. https://doi.org/10.1038/s41582-019-0284-z.
- 10.
Aviram, J.; Vysotski, Y.; Berman, P.; et al. Migraine frequency decrease following prolonged medical cannabis treatment: A cross-sectional study. Brain Sci. 2020, 10, 360. https://doi.org/10.3390/brainsci10060360.
- 11.
Leroux, E.; Taifas, I.; Valade, D.; et al. Use of cannabis among 139 cluster headache sufferers. Cephalalgia 2013, 33, 208–213. https://doi.org/10.1177/0333102412468669.
- 12.
Cuttler, C.; Spradlin, A.; Cleveland, M.J.; et al. Short-and long-term effects of cannabis on headache and migraine. J. Pain 2020, 21, 722–730. https://doi.org/10.1016/j.jpain.2019.11.001.
- 13.
Lochte, B.C.; Beletsky, A.; Samuel, N.K.; et al. The use of cannabis for headache disorders. Cannabis Cannabinoid Res. 2017, 2, 61–71. https://doi.org/10.1089/can.2016.0033.
- 14.
Sexton, M.; Cuttler, C.; Finnell, J.S.; et al. A cross-sectional survey of medical cannabis users: Patterns of use and perceived efficacy. Cannabis Cannabinoid Res. 2016, 1, 131–138. https://doi.org/10.1089/can.2016.0007.
- 15.
Rhyne, D.N.; Anderson, S.L.; Gedde, M.; et al. Effects of medical marijuana on migraine headache frequency in an adult population. Pharmacother. J. Hum. Pharmacol. Drug Ther. 2016, 36, 505–510. https://doi.org/10.1002/phar.1673.
- 16.
Stith, S.S.; Diviant, J.P.; Brockelman, F.; et al. Alleviative effects of Cannabis flower on migraine and headache. J. Integr. Med. 2020, 18, 416–424. https://doi.org/10.1016/j.joim.2020.07.004.
- 17.
Baron, E.P.; Lucas, P.; Eades, J.; et al. Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort. J. Headache Pain 2018, 19, 37. https://doi.org/10.1186/s10194-018-0862-2.
- 18.
Schuster, N.; Wallace, M.; Buse, D.; et al. Vaporized Cannabis versus Placebo for Acute Migraine: A Randomized Controlled Trial (S22. 010). In Neurology; Lippincott Williams & Wilkins: Hagerstown, MD, USA, 2024. https://doi.org/10.1101/2024.02.16.24302843.
- 19.
Stewart, W.F.; Lipton, R.B.; Dowson, A.J.; et al. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001, 56, S20–S28. https://doi.org/10.1212/wnl.56.suppl_1.s20.
- 20.
Kawata, A.K.; Coeytaux, R.R.; DeVellis, R.F.; et al. Psychometric properties of the HIT-6 among patients in a Headache-Specialty practice. Headache J. Head Face Pain 2005, 45, 638–643. https://doi.org/10.1111/j.1526-4610.2005.05130.x.
- 21.
Falavigna, A.; de Souza Bezerra, M.L.; Teles, A.R.; et al. Consistency and reliability of the Brazilian Portuguese version of the Mini-Sleep Questionnaire in undergraduate students. Sleep Breath. 2011, 15, 351–355. https://doi.org/10.1007/s11325-010-0392-x.
- 22.
Balalla, S.K.; Medvedev, O.N.; Siegert, R.J.; et al. Validation of the WHOQOL-BREF and shorter versions using Rasch analysis in traumatic brain injury and orthopedic populations. Arch. Phys. Med. Rehabil. 2019, 100, 1853–1862. https://doi.org/10.1016/j.apmr.2019.05.029.
- 23.
Laird, N.M. Statistical analysis of longitudinal studies. Int. Stat. Rev. 2022, 90, S2–S16. https://doi.org/10.1111/insr.12523.
- 24.
Russo, E.B.; Burnett, A.; Hall, B.; et al. Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem. Res. 2005, 30, 1037–1043. https://doi.org/10.1007/s11064-005-6978-1.
- 25.
Wang, Y.; Wang, Q.; Tang, L.; et al. Cannabinoid modulations of pain-and stress-related circuits. Ageing Neurodegener. Dis. 2023, 3, 16. https://doi.org/10.20517/and.2023.19.
- 26.
Kędziora, M.; Boccella, S.; Marabese, I.; et al. Inhibition of anandamide breakdown reduces pain and restores LTP and monoamine levels in the rat hippocampus via the CB1 receptor following osteoarthritis. Neuropharmacology 2023, 222, 109304. https://doi.org/10.1016/j.neuropharm.2022.109304.
- 27.
Cui, C.; Luo, G.; Lei, J.; et al. Cannabinoid CB1 receptor in dopaminergic circuit from ventral tegmental area to nucleus accumbens links trait anxiety with reward learning. Transl. Psychiatry 2025, 15, 395. https://doi.org/10.1038/s41398-025-03644-5.
- 28.
Bányai, B.; Vass, Z.; Kiss, S.; et al. Role of CB1 cannabinoid receptors in vascular responses and vascular remodeling of the aorta in female mice. Int. J. Mol. Sci. 2023, 24, 16429. https://doi.org/10.3390/ijms242216429.
- 29.
Loder, E. Triptan therapy in migraine. N. Engl. J. Med. 2010, 363, 63–70. https://doi.org/10.1056/NEJMct0910887.
- 30.
Hamel, E.; Currents, H. Serotonin and Migraine: Biology and Clinical Implications. Cephalalgia 2007, 27, 1293–1300. https://doi.org/10.1111/j.1468-2982.2007.01476.x.
- 31.
Iftinca, M.; Defaye, M.; Altier, C. TRPV1-targeted drugs in development for human pain conditions. Drugs 2021, 81, 7–27. https://doi.org/10.1007/s40265-020-01429-2.
- 32.
Gao, N.; Li, M.; Wang, W.; et al. The dual role of TRPV1 in peripheral neuropathic pain: Pain switches caused by its sensitization or desensitization. Front. Mol. Neurosci. 2024, 17, 1400118. https://doi.org/10.3389/fnmol.2024.1400118.
- 33.
Laprairie, R.B.; Bagher, A.M.; Kelly, M.E.M.; et al. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br. J. Pharmacol. 2015, 172, 4790–4805. https://doi.org/10.1111/bph.13250.
- 34.
Billard, E.; Torbey, A.; Inserra, A.; et al. Pharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT2A receptor. Cell. Signal. 2025, 127, 111588. https://doi.org/10.1016/j.cellsig.2025.111588.
- 35.
Moldrich, G.; Wenger, T. Localization of the CB1 cannabinoid receptor in the rat brain. An immunohistochemical study☆. Peptides 2000, 21, 1735–1742. https://doi.org/10.1016/s0196-9781(00)00324-7.
- 36.
Gong, J.P.; Onaivi, E.S.; Ishiguro, H.; et al. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Res. 2006, 1071, 10–23. https://doi.org/10.1016/j.brainres.2005.11.035.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Suite 4002 Level 4, 447 Collins Street, Melbourne, Victoria 3000, Australia
General Inquiries: info@sciltp.com